Literature DB >> 16022911

Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis.

Juan P Wisnivesky1, Claudia Henschke, Thomas McGinn, Michael C Iannuzzi.   

Abstract

PURPOSE: To evaluate the prognostic significance of tumor and node status among patients with Stage II non-small cell lung cancer using a population-based national database.
METHODS: We identified all primary cases of Stage II non-small cell lung cancer diagnosed prior to autopsy from the Surveillance, Epidemiology and End Results (SEER) registry. Lung cancer-specific survival curves were obtained for the 5254 patients who had curative surgical resection, stratifying for tumor and node status (T1-2N1M0, T3N0M0). The 12.5-year Kaplan-Meier estimator of survival was used as a measure of lung cancer cure rate. The influence of gender, age, cell type, pathologic tumor status, nodal metastasis, surgical method, and post-operative radiation therapy were evaluated using Cox regression.
RESULTS: Survival was better for T1N1 cases during the first 3--4 years after diagnosis. Five-year survival for T1N1 and T3N0 cases however, was not significantly different (46% versus 48%, p=0.4) and the cure rate was somewhat higher for T3N0 cases (33% versus to 27%, p=0.10). T2N1 cases had the worst overall survival. Multivariate analysis revealed that gender, age, tumor and nodal status, and histology were independent prognostic factors.
CONCLUSIONS: Among Stage II cancers, T3N0 cases have the highest cure rate and an overall survival pattern that more closely resembles T1N1 tumors. Several clinico-pathologic characteristics are significantly associated with survival and may explain some of the heterogeneity in outcomes among Stage II patients. These results suggest that T3N0 cases may be better classified as Stage IIA disease.

Entities:  

Mesh:

Year:  2005        PMID: 16022911     DOI: 10.1016/j.lungcan.2005.02.010

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients.

Authors:  Bing-Yen Wang; Jing-Yang Huang; Heng-Chung Chen; Ching-Hsiung Lin; Sheng-Hao Lin; Wei-Heng Hung; Ya-Fu Cheng
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-08       Impact factor: 4.553

2.  Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer.

Authors:  David J Stewart; Carmen Behrens; Jack Roth; Ignacio I Wistuba
Journal:  Lung Cancer       Date:  2011-02       Impact factor: 5.705

3.  Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns.

Authors:  Stephen J Shamp; Saad Sheikh; Tangel Chang; Nicholas Damico; Phillip Linden; Afshin Dowlati; Mitchell Machtay; Tithi Biswas
Journal:  J Radiosurg SBRT       Date:  2021

4.  Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities.

Authors:  Stacyann Bailey; Qian Wang; Chung Yin Kong; Kimberly Stone; Rajwanth Veluswamy; Susan E Bates; Cardinale B Smith; Juan P Wisnivesky; Keith Sigel
Journal:  Curr Probl Cancer       Date:  2022-05-21       Impact factor: 2.367

5.  Clinical outcomes and changes in lung function after segmentectomy versus lobectomy for lung cancer cases.

Authors:  Bo Deng; Stephen D Cassivi; Mariza de Andrade; Francis C Nichols; Victor F Trastek; Yi Wang; Jason A Wampfler; Shawn M Stoddard; Dennis A Wigle; Robert K Shen; Mark S Allen; Claude Deschamps; Ping Yang
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-20       Impact factor: 5.209

Review 6.  Prognostic and predictive biomarkers post curative intent therapy.

Authors:  Rebecca Feldman; Edward S Kim
Journal:  Ann Transl Med       Date:  2017-09

7.  [The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer].

Authors:  Kari Chansky; Jean-Paul Sculier; John J Crowley; Dori Giroux; Jan Van Meerbeeck; Peter Goldstraw
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-01

8.  Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure.

Authors:  Atsuya Narita; Atsuya Takeda; Takahisa Eriguchi; Yusuke Saigusa; Naoko Sanuki; Yuichiro Tsurugai; Tatsuji Enomoto; Hidehiko Kuribayashi; Tomikazu Mizuno; Kae Yashiro; Yu Hara; Takeshi Kaneko
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724

9.  Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma.

Authors:  Brooks P Leitner; Kevin B Givechian; Shyryn Ospanova; Aray Beisenbayeva; Katerina Politi; Rachel J Perry
Journal:  NPJ Precis Oncol       Date:  2022-01-27

10.  The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients.

Authors:  Paweł Krawczyk; Kamila Wojas; Janusz Milanowski; Jacek Roliński
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-12-03       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.